CD47 and hematologic disorder: In contrast, a multicenter, open-label, first-in-human phase 1 study of TTI-621 was conducted, wherein a recombinant soluble fusion protein composed of the CD47-binding domain of human SIRPα and the Fc region of human IgG1 [63], binds to CD47 in patients with R/R hematologic malignancies [31].